References
Original article
Wang, K. et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat. Med. https://doi.org/10.1038/s41591-023-02786-7 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hindson, J. Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence. Nat Rev Gastroenterol Hepatol 21, 141 (2024). https://doi.org/10.1038/s41575-024-00904-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-024-00904-5
- Springer Nature Limited